Angiotensin II Type 1 Receptor Blockade Prevents Lethal Malignant Hypertension
Relation to Kidney Inflammation

Karl F. Hilgers, MD; Andrea Hartner, PhD; Markus Porst, PhD; Roland Veelken, MD; Johannes F.E. Mann, MD

Background—Angiotensin II is elevated in malignant hypertension. We tested the hypothesis that angiotensin II type 1 receptor blockade can prevent the development of malignant hypertension even in the absence of a blood pressure–lowering effect.

Methods and Results—Two-kidney, 1-clip rats were followed up for 28 days; blood pressure was measured by tail-cuff plethysmography and intra-arterially. After a 2-week run-in phase, rats received valsartan at a dose of 0.3 (n=14) or 3 (n=12) mg · kg⁻¹ · d⁻¹ or solvent (n=27). Only the higher dose of valsartan, but not the lower dose, decreased blood pressure. Both doses of valsartan prevented the development of lethal malignant hypertension. Twenty of 27 solvent-treated renovascular hypertensive rats died, but only 3 of 14 rats treated with the low dose and 1 of 12 rats treated with the high dose of valsartan died. Histological signs of malignant nephrosclerosis were found in all rats examined that had died throughout the study and in 6 of 7 surviving solvent-treated renovascular hypertensive animals. Increased expression of monocyte chemoattractant protein-1 and prominent interstitial influx of macrophages occurred in the nonclipped kidneys exposed to high pressure in solvent-treated rats. These alterations were prevented by valsartan at both doses, irrespective of blood pressure effects.

Conclusions—Angiotensin II type 1 receptor blockade by valsartan prevents lethal malignant hypertension independently of blood pressure. The results suggest that reduction of angiotensin-induced inflammation in the kidney may contribute to the protective effects of valsartan. (Circulation. 2001;104:1436-1440.)

Key Words: angiotensin • hypertension • kidney • leukocytes • survival

Malignant hypertension is characterized by rapidly progressive target-organ injury, often out of proportion to the level of blood pressure itself. Injury to the kidney is an important feature of malignant hypertension. Moreover, the kidney plays a key role in the development of malignant hypertension: salt wasting and alterations in intrarenal hemodynamics are hallmarks of early malignant nephrosclerosis.¹,² Recent studies have reinforced the notion that angiotensin (Ang) II plays an important role in the development of malignant hypertension. Using different transgenic rat models characterized by overexpression of genes of the renin-angiotensin system, Montgomery et al³ and Mervaala et al⁴-⁵ showed that blockade of Ang II prevented the development of malignant hypertension in these models. These authors provided some evidence that inhibition of converting enzyme³ and renin⁴ were effective even if blood pressure was not lowered. Blood pressure, however, was assessed only by the tail-cuff measurements in anesthetized animals.

We tested the hypothesis that inhibition of the action of Ang II on its type 1 receptor (AT₁)⁶ prevents the occurrence of lethal malignant hypertension independently of blood pressure lowering. Blood pressure was measured intra-arterially. We studied the occurrence of malignant nephrosclerosis in the 2-kidney, 1-clip (2K1C) model of renovascular hypertension, which is comparable to renovascular hypertension in humans. Infiltration of macrophages, which occurs in the kidney exposed to high blood pressure,⁷,⁸ was investigated as a potential nonhemodynamic mechanism.

Methods

Renovascular Hypertension
Rats were housed in a room maintained at 22±2°C, exposed to a 12-hour dark/light cycle. The animals were allowed unlimited access to chow (No. 1320, Altromin) and tap water. All procedures performed on animals were done in accordance with NIH guidelines.

Received February 13, 2001; revision received May 30, 2001; accepted June 2, 2001.
From the Department of Medicine IV, University of Erlangen, Nürnberg (K.F.H., A.H., M.P., R.V.); the Department of Medicine VI, Schwabing General Hospital, Ludwig-Maximilians-University, Munich (J.F.E.M.); and the German Institute for High Blood Pressure Research, Heidelberg (K.F.H., R.V., J.F.E.M.), Germany.
Reprint requests to Karl F. Hilgers, MD, Nephrology Research Laboratory, Loschgestrasse 8, D-91054 Erlangen, Germany. E-mail karl.hilgers@rzmail.uni-erlangen.de
© 2001 American Heart Association, Inc.

Circulation is available at http://www.circulationaha.org

1436
and were approved by the local government authorities (Regierung von Mittelfranken, AZ No. 621-2531.3-10/94).

2KIC renovascular hypertension was induced in male Sprague-Dawley rats (Charles River, Sulzfeld, Germany) weighing 150 to 170 g by placing a silver clip of 0.2-mm ID around the left renal artery through a flank incision under anesthesia with ketamine/xylazine as previously described. Control animals underwent sham operation without placement of the clip. Weight and systolic blood pressure (by tail-cuff plethysmography) were measured weekly.

Treatment

After 2 weeks, only animals with systolic blood pressure (>150 mm Hg, which was achieved in 80% to 90% of all renal-clip animals, were included in the 2KIC groups. Rats were treated with 2 doses of the AT1 antagonist (AT1 RA) valsartan or placebo. Twelve 2KIC rats and 5 sham-operated rats received 3 mg · kg−1 · d−1 AT1 RA, 14 2KIC rats received 0.3 mg · kg−1 · d−1 valsartan, and 27 2KIC rats and 10 sham-operated rats received solvent. Osmotic minipumps (Alzet model 2002, Alza) that delivered 0.5 µL/h for 14 days were implanted in the peritoneal cavity through a small midline incision under ether anesthesia. Valsartan (55.8 mg/mL for the higher dose and 5.58 mg/mL for the lower dose) was dissolved in 0.46 mol/L KOH (pH 7.2). Animals were followed up for 14 days.

To obtain better measurements of blood pressure during treatment, we performed an additional study. Two weeks after clipping, 6 2KIC rats and 2 2KIC animals were treated with the low dose of AT1 RA, and 8 2KIC and 5 sham-operated animals received solvent. After 9 days of treatment, all animals were instrumented with femoral artery catheters for intra-arterial blood pressure measurements under ether anesthesia as described previously. Measurements were performed on the same day 4 hours after termination of anesthesia via transducers connected to a polygraph (Hellige).

After the organs had been weighed, kidneys were decapsulated. Part of each kidney was immediately snap-frozen on liquid nitrogen for protein and RNA extraction, and a second part was put in formalin for immunohistochemical detection of macrophages (monoclonal ED-1 monoclonal antibody, Dianova). After overnight fixation in methyl–Carnoy solution, tissues were dehydrated and embedded in paraffin. Sections (2 mm) were cut with a Leitz SM 2000 R microtome (Leica Instruments). After deparaffinization and blockade of endogenous peroxidase activity, the immunohistochemical detection of macrophages (monopolonclonal ED-1 antibody, Biozol), macrophage chemoattractant protein–1 (MCP-1; polyclonal rabbit antiserum kindly provided by Dr T. Yoshimura, National Cancer Institute, Frederick, Md), and collagen I (Biozol) was performed as previously described. The Vectastain DAB kit (Vector Laboratory) was used as a chromogen. Each slide was counterstained with hematoxylin. Renal interstitial macrophages were counted as described previously in 30 medium-power (magnification ×250) cortical views per section and expressed as cells mm−2. Interstitial collagen I was quantified in 30 medium-power views by means of an 11×11-point grid. The percentage of grid points corresponding to a stained area was calculated.

Immunohistochemistry of Kidney Sections

After overnight fixation in methyl–Carnoy solution, tissues were dehydrated and embedded in paraffin. Sections (2 mm) were cut with a Leitz SM 2000 R microtome (Leica Instruments). After deparaffinization and blockade of endogenous peroxidase activity, the immunohistochemical detection of macrophages (monopolonclonal ED-1 antibody, Biozol), macrophage chemoattractant protein–1 (MCP-1; polyclonal rabbit antiserum kindly provided by Dr T. Yoshimura, National Cancer Institute, Frederick, Md), and collagen I (Biozol) was performed as previously described. The Vectastain DAB kit (Vector Laboratory) was used as a chromogen. Each slide was counterstained with hematoxylin. Renal interstitial macrophages were counted as described previously in 30 medium-power (magnification ×250) cortical views per section and expressed as cells mm−2. Interstitial collagen I was quantified in 30 medium-power views by means of an 11×11-point grid. The percentage of grid points corresponding to a stained area was calculated.

Northern and Western Blot for MCP-1 mRNA and Protein

RNA and protein were extracted from kidney cortical tissue by use of TRI reagent (MRC Inc). Northern blot analysis was performed with full-length rat MCP-1 cDNA as described previously. Western blot was performed after proteins had been separated with a denaturing 10% to 18% SDS–polyacrylamide gradient gel in the buffer system described by Schägger and von Jagow. The membrane was incubated in a 1:1000 dilution of an MCP-1 antibody and a peroxidase-conjugated secondary antibody, followed by luminescence immunodetection (ECL, Amersham). The x-ray films used for detection were then analyzed by densitometry.

Results

On the basis of weight measurements, rats treated with low-dose AT1 RA received a mean dose of 0.32 mg · kg−1 · d−1 valsartan (SD 0.05 mg · kg−1 · d−1), and high-dose AT1 RA–treated animals received a mean dose of 3.05 mg · kg−1 · d−1 (SD 0.44 mg · kg−1 · d−1). Systolic blood pressure was reduced but not normalized by high-dose AT1 RA, whereas blood pressure was not altered by low-dose AT1 RA (Figure 1A). Untreated 2KIC rats showed substantial mortality (20 of 27 rats) during the study (Figure 1B). Death was usually preceded by 3 to 5 days of weight loss. Both high- and low-dose regimens of AT1 RA prevented mortality (Figure 1B).

In an additional study with intra-arterial blood pressure recordings, 5 rats of each group survived to the day of measurement. Intra-arterial measurements confirmed that mean blood pressure was not affected by low-dose AT1 RA and was lowered but not normalized by the higher dose of valsartan (Figure 2A).

The Table shows body weight and the ratios of heart and kidney weights to body weight. Both doses of valsartan decreased the weight of the nonclipped, contralateral kidney and of the heart. The higher dose was significantly more effective in lowering heart weight (Table). Valsartan caused a dose-dependent decrease of the weight of the clipped kidney (Table). In sham-operated, normotensive rats, high-dose
AT1 RA had no effect on blood pressure or organ weight (data not shown).

Screening by light microscopy of routine kidney sections of all surviving animals and 11 that had died for signs of malignant hypertension (fibrinoid necrosis and/or onion-shaped vascular cell proliferative lesions) revealed the presence of these changes in all animals that had died throughout the study, in all but 1 (6 of 7) surviving solvent-treated 2K1C rats, and in 4 of 11 low-dose AT1 RA-treated 2K1C but not in any sham-operated or high-dose AT1 RA–treated rat (see Figure 3 for examples).

Extracellular matrix accumulation in the nonclipped kidney exposed to high blood pressure was demonstrated by quantification of interstitial collagen I in 2K1C rats (16.7 ± 1.7% versus 6.4 ± 0.9% of cortical area in sham-operated rats, \( P < 0.01 \)). Collagen I was decreased by low-dose valsartan (12.1 ± 2.3%, \( P < 0.05 \) versus untreated 2K1C), and to an even greater degree by high-dose valsartan (8.3 ± 2.2%, \( P < 0.01 \) versus untreated 2K1C, \( P < 0.05 \) versus low-dose valsartan).

There were more interstitial macrophages in the nonclipped kidney exposed to high blood pressure of 2K1C animals than in normal kidneys (Figure 2B). High- and low-dose regimens of AT1 RA decreased macrophage infiltration to the same degree (Figure 2B). MCP-1 mRNA was increased significantly, to 172 ± 8% of control levels in the nonclipped kidneys of 2K1C (Figure 4A). Valsartan blunted the increase of MCP-1 mRNA (101 ± 20% of control levels at the low dose and 72 ± 7% at the high dose, \( P < 0.05 \)). The elevation of MCP-1 protein (206 ± 3% of control levels, \( P < 0.05 \)) was also blunted by both doses of AT1 RA (95 ± 6% of control levels at the low dose and 86 ± 9% at the high dose, \( P < 0.05 \), Figure 4B). By immunohistochemistry, MCP-1 protein was detected in vascular smooth muscle cells, interstitial cells, glomerular epithelial cells, macrophages, and occasionally but rarely in tubular cells in the nonclipped

### Table: Body Weight and Organ Wt/Body Wt Ratios

<table>
<thead>
<tr>
<th>Experimental Group</th>
<th>Body Weight, g</th>
<th>Left Kidney/Body Wt Ratio, mg/kg</th>
<th>Right Kidney/Body Wt Ratio, mg/kg</th>
<th>Heart/Body Wt Ratio, mg/kg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sham-operated rats (n=15)</td>
<td>320 ± 4</td>
<td>3.50 ± 0.02</td>
<td>3.53 ± 0.03</td>
<td>3.40 ± 0.05</td>
</tr>
<tr>
<td>Untreated 2K1C rats (n=7)</td>
<td>166 ± 11*</td>
<td>3.49 ± 0.11</td>
<td>7.47 ± 0.51</td>
<td>6.57 ± 0.33*</td>
</tr>
<tr>
<td>2K1C/AT1RA low dose (n=11)</td>
<td>228 ± 11†</td>
<td>2.94 ± 0.27†</td>
<td>5.31 ± 0.28†</td>
<td>5.35 ± 0.22†</td>
</tr>
<tr>
<td>2K1C/AT1RA high dose (n=11)</td>
<td>263 ± 9‡‡</td>
<td>2.43 ± 0.22‡‡</td>
<td>5.21 ± 0.22‡‡</td>
<td>4.56 ± 0.29‡‡</td>
</tr>
</tbody>
</table>

\( *P < 0.05 \) vs sham operation; `significant differences in AT1RA-treated vs untreated 2K1C; †\( P < 0.05 \) between the high and the low dose of AT1RA.
Discussion

Our results show that blockade of the AT₁ receptor by valsartan prevents the development of lethal malignant hypertension in renovascular hypertensive rats even if blood pressure is not decreased. Furthermore, the data suggest that AT₁-mediated nonpressor, proinflammatory effects, i.e., induction of the chemokine MCP-1 and macrophage infiltration, may contribute to the development of malignant hypertension.

Our observation that AT₁ blockade prevented malignant hypertension regardless of its effect on blood pressure confirms and extends recent reports in other models of malignant hypertension in the rat. Montgomery et al. showed that ACE inhibition lowered the frequency of malignant hypertension in Ren2-transgenic hypertensive rats. These authors used a dose of ACE inhibition that did not lower systolic blood pressure as measured by a tail-cuff method under anesthesia, but they did not perform intra-arterial recordings. Mervaala and coworkers used a new transgenic rat model with extreme overexpression of the human renin and angiotensinogen genes, which leads to early mortality in all rats. In these animals, mortality could be prevented if blood pressure was lowered with blockers of the renin-angiotensin system but not with a conventional triple therapy, despite comparable antihypertensive efficacy, as judged from tail-cuff measurements.

Unlike these transgenic models of malignant hypertension, which are characterized by an extreme overexpression of genes of the renin-angiotensin system and are therefore expected to be dependent on Ang II, renovascular hypertension is an important cause of high blood pressure in human patients. The prevalence of renovascular hypertension among all hypertensive patients is subject to debate (for review see Conlon et al. and appears to be lower than previously thought. There is little doubt, however, that renovascular hypertension is associated with a higher cardiovascular morbidity and mortality than essential hypertension. Rats with unilateral renal artery clips develop renovascular hypertension and malignant hypertension in a predictable manner, depending on the size of the animal and the ID of the clip. Death from malignant hypertension is usually preceded by several days of volume and weight loss.

Our results demonstrate an important role of the AT₁ receptor for the development of malignant hypertension. The AT₁ receptor antagonist valsartan prevented lethal malignant hypertension even when blood pressure was not affected. To avoid a possible selection bias due to mortality of the animals with the highest blood pressure levels, we measured intra-arterial blood pressure in a second group of animals followed up for a somewhat shorter time. In addition to our blood pressure measurements, the notion that 0.3 mg kg⁻¹ d⁻¹ valsartan has no important effect on blood pressure is also supported by previous reports from other laboratories, including telemetric measurements performed by Webb et al. These authors reported only minute effects of a somewhat higher dose of valsartan, 0.5 mg kg⁻¹ d⁻¹, on blood pressure. In the absence of telemetric measurements, we cannot exclude such minute effects in our study, but we consider it highly unlikely that the massive effects of valsartan on survival can be explained solely by lowering of the mean arterial blood pressure by some 5 mm Hg. Interestingly, blockade of the renin-angiotensin system was reported to improve survival in scleroderma renal crisis, another form of thrombotic microangiopathy in the kidney. Thus, our data may have implications for human renal diseases beyond renovascular hypertension.

We do not try, however, to dispute the importance of high blood pressure for target organ damage. Some aspects of organ protection by valsartan were clearly dependent on blood pressure itself: both the organ weights and the measurement of renal interstitial collagen I indicate that the higher dose of valsartan, which lowered blood pressure, caused a greater amelioration of heart hypertrophy and nephrosclerosis. Unfortunately, the higher dose of valsartan also induced a more pronounced weight loss of the poststenotic left kidney, reminiscent of previous reports on the effects of ACE inhibition on the poststenotic kidney. Which factor(s) might explain the blood pressure–independent effect of valsartan on survival? We think that our data support the notion that AT₁-mediated proinflammatory effects are important for the development of lethal malignant nephrosclerosis. We and others have previously shown that a marked infiltration of macrophages into the kidney occurs in angiotensin-dependent forms of hypertension, including Ang II infusion, renovascular hypertension, and overexpression of genes of the renin-angiotensin system in transgenic rats. Interstitial macrophage infiltration was decreased by valsartan regardless of whether or not blood pressure was affected.

The influx of macrophages may be due to AT₁-mediated induction of the chemokine MCP-1. Ang II has been shown to induce MCP-1 expression via AT₁ in vascular smooth mus-
molecules might also contribute sary for macrophage infiltration in aortic tissue in atheroscle-

10. Schagger H, von Jagow G. Tricine-sodium dodecyl sulfate-polyacryl-

amide gel electrophoresis for the separation of proteins in the range from 1 to 100 kDa. Anal Biochem. 1987;166:368–379.


13. Zierhut W, Studer R, Laurent D, et al. Left ventricular wall stress and sarcoplasmic reticulum Ca2+-ATPase gene expression in renal hyper-


28. Wada T, Yokoyama H, Furuichi K, et al. Intervention of crescentic glomerulonephritis, however, support the notion that MCP-1 and because AT1 may activate macrophages directly. 26,27


Angiotensin II Type 1 Receptor Blockade Prevents Lethal Malignant Hypertension: Relation to Kidney Inflammation
Karl F. Hilgers, Andrea Hartner, Markus Porst, Roland Veelken and Johannes F.E. Mann

Circulation. 2001;104:1436-1440
doi: 10.1161/hc3601.095576
Circulation is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2001 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7322. Online ISSN: 1524-4539

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circ.ahajournals.org/content/104/12/1436

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation is online at:
http://circ.ahajournals.org/subscriptions/